To test the potency of vismodegib in blocking growth of BCCs in our murine model of NBCCS, we administered vismodegib (40 mg/kg body weight by mouth) to Ptch1+/−/SKH-1 mice thirty minutes prior to each exposure to UVB and assessed its protective effects against UVB-induced BCCs. The gene discussed is PTCH1; the disease is nevoid basal cell carcinoma syndrome.